Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Bullboard Posts
Comment by longterm56on Jul 03, 2018 8:33pm
199 Views
Post# 28264966

RE:RE:Forward Guidance on Earnings

RE:RE:Forward Guidance on Earnings
SPCEO1 wrote:
longterm56 wrote:
Clearly the most important issue at Thursday's conference call is forward guidance on earnings.  Will TH management actually give numbers or will they keep mumbling under their breath something like "everythings great"?  I am anxious for specifics ...

  -LT


They might update their guidance for Egrifta but I suspect it is too early for them to give us Trogarzo guidance. Hopefully, I wrong about that but more likely is we will get very straightforward encouraging words (not mumblings which I beleive you incorrectly suggest is the norm) about the trend in Trogarzo sales. 

What we really need is for the RBC analyst to weigh in with a report on TH after the call, The 4 remaining analysts do not have much impact in the market due to their small size. TH needs and deserves analyst coverage from more impactful brokers. 


To be honest, SPCE01, you have somewhat rose-colored glasses on when evaluating THERF comments and PRs.  We appreciate your engagement with THERF, but at somepoint you need to be more neutral in your evaluation of press releases.  We haven't seen a whole lot recently, so I have curbed my enthusiasm until we get some *!#$%*%*$ details! 

  -LT

Bullboard Posts